The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
Biomarker
clinical trial
docetaxel
gemcitabine
immune microenvironment
survival
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
11 05 2021
11 05 2021
Historique:
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcitabine, are mediated through enhanced antitumor immune responses. The objective of this study was to use material from a randomized clinical trial to evaluate whether patients with preexisting immune infiltrates responded better to treatment with gemcitabine + docetaxel (GD) compared to docetaxel alone. Formalin fixed, paraffin-embedded breast cancer tissues from SBG0102 phase 3 trial patients randomly assigned to treatment with GD or docetaxel were used. Immunohistochemical staining for CD8, FOXP3, LAG3, PD-1, PD-L1 and CD163 was performed. Tumor infiltrating lymphocytes (TILs) and tumor associated macrophages were evaluated. Prespecified statistical analyses were performed in a formal prospective-retrospective design. Time to progression was primary endpoint and overall survival secondary endpoint. Correlations between biomarker status and endpoints were evaluated using the Kaplan-Meier method and Cox proportional hazards models. Biomarker data was obtained for 237 patients. There was no difference in treatment effect according to biomarker status for the whole cohort. In planned subgroup analysis by PAM50 subtype, in non-luminal (basal-like and HER2E) breast cancers FOXP3 was a significant predictor of treatment effect with GD compared to docetaxel, with a HR of 0.22 (0.09-0.52) for tumors with low FOXP3 compared to HR 0.92 (0.47-1.80) for high FOXP3 TILs (P
Identifiants
pubmed: 34026336
doi: 10.1080/2162402X.2021.1924492
pii: 1924492
pmc: PMC8118411
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Docetaxel
15H5577CQD
Gemcitabine
0
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1924492Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Clin Cancer Res. 2008 Jun 1;14(11):3536-44
pubmed: 18519787
Mod Pathol. 2016 Oct;29(10):1155-64
pubmed: 27363491
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Exp Cell Res. 2018 Jan 15;362(2):525-531
pubmed: 29269075
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
J Immunother Cancer. 2019 Oct 18;7(1):265
pubmed: 31627744
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248
pubmed: 29367423
Ann Oncol. 2021 Aug;32(8):994-1004
pubmed: 34219000
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016
pubmed: 33523233
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
J Pathol. 2020 Apr;250(5):667-684
pubmed: 32129476
Clin Cancer Res. 2010 Sep 15;16(18):4583-94
pubmed: 20702612
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4
pubmed: 16106022
Int J Cancer. 2019 May 15;144(10):2578-2586
pubmed: 30411790
Expert Opin Biol Ther. 2021 Mar;21(3):311-322
pubmed: 32954871
Cancers (Basel). 2021 Mar 01;13(5):
pubmed: 33804486
Front Oncol. 2020 Oct 20;10:553080
pubmed: 33194613
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Expert Opin Biol Ther. 2020 Aug 9;:1-12
pubmed: 32713217
J Natl Cancer Inst. 2018 Jun 1;110(6):568-580
pubmed: 29315431
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33239417
Prostate. 2020 Jul;80(10):742-752
pubmed: 32449811
Transl Oncol. 2020 Mar;13(3):100743
pubmed: 32145636
Biomaterials. 2019 Jan;189:48-59
pubmed: 30388589
Clin Cancer Res. 2008 Mar 1;14(5):1423-30
pubmed: 18316565
BMC Cancer. 2020 Mar 4;20(1):179
pubmed: 32131780
Oncoimmunology. 2018 Mar 06;7(6):e1438107
pubmed: 29930882
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489
pubmed: 32259782
Front Immunol. 2019 Jul 17;10:1654
pubmed: 31379850
Cancer Sci. 2017 May;108(5):853-858
pubmed: 28267224
Cancer Res. 2017 Nov 1;77(21):5952-5962
pubmed: 28765154
Acta Oncol. 2014 Jun;53(6):776-87
pubmed: 24359601
Mol Immunol. 2019 May;109:140-148
pubmed: 30951933
Br J Cancer. 2018 Feb 20;118(4):480-488
pubmed: 29370583
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
Ann Oncol. 2017 Dec 1;28(12):2977-2984
pubmed: 29045526
J Clin Oncol. 2011 Dec 20;29(36):4748-54
pubmed: 22084374
Eur J Immunol. 2004 Feb;34(2):336-44
pubmed: 14768038
Clin Cancer Res. 2008 Mar 1;14(5):1368-76
pubmed: 18316557
J Clin Oncol. 2006 Dec 20;24(36):5637-44
pubmed: 17116944
Front Immunol. 2020 Feb 25;11:331
pubmed: 32161598
Int J Cancer. 2013 Aug 1;133(3):624-36
pubmed: 23364915
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Breast Cancer Res. 2014 Sep 06;16(5):432
pubmed: 25193543
J Clin Oncol. 2008 Dec 10;26(35):5697-704
pubmed: 19001334
JAMA Oncol. 2017 Nov 9;3(11):e172085
pubmed: 28750133
Breast Cancer Res. 2018 Jun 22;20(1):62
pubmed: 29929548